CLIMB BIO, INC. Other Restructuring Costs
CLIMB BIO, INC. (CLYM) reported Other Restructuring Costs of $23.00 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherRestructuringCosts · last filed 2023-11-14
- CLIMB BIO, INC. other restructuring costs for the quarter ending 2023-09-30 was -$77.00K.
- CLIMB BIO, INC. other restructuring costs for the quarter ending 2023-06-30 was $0.00.
- CLIMB BIO, INC. other restructuring costs for the quarter ending 2023-03-31 was $100.00K.
| Period end | Other Restructuring Costs 3 month | Other Restructuring Costs 6 month | Other Restructuring Costs 9 month |
|---|---|---|---|
| 2023-09-30 | -$77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$77.00K derived: sum of 2 quarters · filed 2023-11-14 | $23.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $100.00K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $100.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |